Significant Accounting Policies - Additional Information (Detail) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Summary Of Significant Accounting Policies [Line Items]
Net sales	$ 108,537,000	$ 98,497,000	$ 104,075,000	$ 98,679,000	$ 104,622,000	$ 101,151,000	$ 100,954,000	$ 89,762,000	$ 409,788,000	$ 396,489,000	$ 402,277,000
Cumulative-effect adjustment to retained earnings									604,000
Decrease in net cash provided by financing activities									46,112,000	(24,728,000)	20,200,000
Increase in net cash from operating activities									44,707,000	43,610,000	51,164,000
ASU 2016-09 [Member]
Summary Of Significant Accounting Policies [Line Items]
Cumulative-effect adjustment to retained earnings									1,400,000
Cumulative-effect adjustment to net assets	$ 600,000								600,000
Decrease in net cash provided by financing activities										400,000	200,000
Increase in net cash from operating activities										400,000	200,000
Musculoskeletal Transplant Foundation ("MTF") [Member]
Summary Of Significant Accounting Policies [Line Items]
Expenditures for other research and development									1,300,000	0	300,000
Customers and Distributors Based in Europe [Member]
Summary Of Significant Accounting Policies [Line Items]
Net sales									60,000,000
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Transactional foreign currency gains and (losses), including those generated from intercompany operations									$ (100,000)	$ (3,500,000)	$ (2,400,000)